Risperidone

"Risperidone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.

Descriptor ID	D018967
MeSH Number(s)	D03.383.742.698.685
Concept/Terms	Risperidone Risperidone Risperdal Consta Risperdal Consta Consta, Risperdal Risperidal Risperidal R-64,766 R-64,766 R 64,766 R64,766 R-64766 R 64766 R64766

Below are MeSH descriptors whose meaning is more general than "Risperidone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidinones [D03.383.742.698]
Risperidone [D03.383.742.698.685]

Below are MeSH descriptors whose meaning is related to "Risperidone".

Below are MeSH descriptors whose meaning is more specific than "Risperidone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Risperidone" by people in this website by year, and whether "Risperidone" was a major or minor topic of these publications.

Bar chart showing 13 publications over 9 distinct years, with a maximum of 3 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2003	1	0	1
2004	1	0	1
2005	3	0	3
2006	2	0	2
2014	0	1	1
2016	2	0	2
2017	1	0	1
2018	0	1	1

Below are the most recent publications written about "Risperidone" by people in Profiles.

Thippaiah SM, Nagaraja S, Birur B, Cohen AW. An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature. Psychopharmacol Bull. 2018 03 13; 48(3):16-21.

View in: PubMed
Foster A, Buckley P, Lauriello J, Looney S, Schooler N. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. J Clin Psychopharmacol. 2017 Oct; 37(5):595-599.

View in: PubMed
Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. Am J Psychiatry. 2017 04 01; 174(4):362-369.

View in: PubMed
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.

View in: PubMed
Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.

View in: PubMed
Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006; 53(3):157-68.

View in: PubMed
Canive JM, Miller GA, Irwin JG, Moses SN, Thoma RJ, Edgar JC, Sherwood A, Torres F, Lanoue M, Lewis S, Hanlon FM, Weisend MP, Mead V, Tuason VB. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Psychopharmacol Bull. 2006; 39(1):105-16.

View in: PubMed
Pinninti NR, Mago R. Injection site pain with long-acting risperidone. J Clin Psychiatry. 2005 May; 66(5):656-7; author reply, 657.

View in: PubMed
Pinninti NR, Mago R. Use of long-acting risperidone. Psychiatr Serv. 2005 Jan; 56(1):105; author reply 106-7.

View in: PubMed
Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res. 2005 Jan 01; 72(2-3):249-58.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement